10 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $10.3B | $157M | 0.0% | 17.7% | $1.0B | $20.8B | $1.3B |
| 2024 | $9.6B | -$46M | 0.0% | 16.1% | $1.3B | $21.6B | $1.2B |
| 2023 | $8.8B | -$592M | 0.0% | 11.0% | $817M | $22.4B | $947M |
| 2022 | $8.1B | -$225M | 0.0% | 5.6% | -$946M | $20.8B | $564M |
| 2021 | $8.4B | -$948M | 0.0% | 5.3% | $1.2B | $22.7B | $582M |
| 2020 | $8.0B | -$560M | 0.0% | 8.4% | $809M | $23.9B | $605M |
| 2019 | $8.6B | -$1.8B | 0.0% | -2.4% | $1.2B | $25.9B | $3.2B |
| 2018 | $8.4B | — | 0.0% | -28.4% | $1.3B | $24.3B | $721M |
| 2017 | $8.7B | — | 71.3% | 1.2% | $2.1B | $25.4B | $720M |
| 2016 | $9.7B | — | 73.4% | -5.9% | $1.9B | $29.9B | $542M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $2.5B | -$1.4B | 0.0% | -37.6% | $121M | $20.8B | $1.3B |
| Dec '25 | $2.8B | -$112M | 0.0% | 17.0% | $403M | $20.8B | $1.3B |
| Sep '25 | $2.7B | $179M | 0.0% | 23.1% | $314M | $21.0B | $1.3B |
| Jun '25 | $2.5B | $148M | 0.0% | 17.5% | $190M | $21.7B | $1.7B |
| Mar '25 | $2.3B | -$58M | 0.0% | 12.2% | $96M | $21.5B | $1.1B |
| Dec '24 | $2.6B | $93M | 0.0% | 21.8% | $495M | $21.6B | $1.2B |
| Sep '24 | $2.5B | -$85M | 0.0% | 12.7% | $334M | $21.5B | $719M |
| Jun '24 | $2.4B | $10M | 0.0% | 16.2% | $302M | $21.7B | $595M |
| Mar '24 | $2.2B | -$64M | 0.0% | 13.1% | $129M | $22.1B | $733M |
| Dec '23 | $2.4B | -$39M | 0.0% | 15.0% | $292M | $22.4B | $947M |
| Sep '23 | $2.2B | -$378M | 0.0% | 0.6% | $240M | $22.4B | $760M |
| Jun '23 | $2.2B | $26M | 0.0% | 19.0% | $178M | $20.6B | $579M |
| Mar '23 | $1.9B | -$201M | 0.0% | 9.0% | $107M | $20.7B | $518M |
| Dec '22 | $2.2B | -$410M | 0.0% | -10.8% | $409M | $20.8B | $564M |
| Sep '22 | $2.0B | $399M | 0.0% | 11.9% | -$1.3B | $21.2B | $486M |
| Jun '22 | $2.0B | -$145M | 0.0% | 8.2% | $71M | $21.8B | $659M |
| Mar '22 | $1.9B | -$69M | 0.0% | 14.9% | -$109M | $23.2B | $1.2B |
| Dec '21 | $2.2B | $69M | 0.0% | 16.7% | -$54M | $22.7B | $582M |
| Sep '21 | $2.1B | $188M | 0.0% | 27.2% | $501M | $22.4B | $690M |
| Jun '21 | $2.1B | -$595M | 0.0% | -12.9% | $333M | $23.4B | $642M |
How the market has priced BHC against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Bausch Health Companies Inc.'s revenue has grown 5.0% per year. These are computed facts, not advice.
As of FY2025, Bausch Health Companies Inc. reported $20.8B of total debt against $1.3B of cash.
In FY2025, gross margin was —, operating margin 17.7%, and net margin 1.5%.
As of Jun '26, Bausch Health Companies Inc. traded at a price-to-earnings ratio of about 12.5× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.